This is significant, as cardiovascular disease is one of the leading causes of death in people with diabetes
Trials with older GLP-1 drugs (liraglutide, exenatide) including the large ADJUNCT ONE and ADJUNCT TWO studies showed modest HbA1c improvements of 0.10.7%, meaningful weight loss, and lower insulin requirements, but also raised early concerns about hypoglycemia and ketosis that kept enthusiasm in check for years
And we were learning a lot of things because you can compare the proteome effects to what has been done in the decode cohort
It has multiple actions including: potentiation of glucose-mediated insulin secretion mechanisms identified: increased -cell proliferation, resulting in an increase -cell mass (Fusco et al, 2017) stimulation of insulin biosynthesis at the translational level, helping to maintain -cell insulin stores and secretory capacity (Baggio & Drucker, 2007) because the GLP-1 effect is glucose-dependent (there is more insulin release when glucose levels are elevated, but less effect when glucose levels are normal), GLP-1 agonists have a lower risk for producing hypoglycemia compared to sulfonylureas (that chronically stimulate insulin release, independent of glucose concentration) suppression of postprandial glucagon release Evidence indicates that stimulation of pancreatic cells by GLP-1 increases their glucose sensitivity, resulting in less glucagon release at any glucose level (Baggio & Drucker, 2007)
The medication is building to therapeutic levels in your blood
